LGI1 and encephalitis: In our cohort, 52.2% of patients had CSF pleocytosis (70.8% for anti-NMDAR encephalitis,18.5% for anti-LGI1 encephalitis, 66.7% for anti-GABABR encephalitis and 16.7% for anti-CASPR2 encephalitis).